Wednesday, 14 October 2026European Markets

Oslo Børs Benchmark Index_GI Bearish By 2% In The Last 24 Hours

Loading stream...

(VIANEWS) - Oslo Børs Benchmark Index_GI (OSEBX.OL) has been up by 2.02% for the last session's close. At 14:50 EST on Tuesday, 4 June, Oslo Børs Benchmark Index_GI (OSEBX.OL) is kr1,413.17.

Volume

Today's last reported volume for Oslo Børs Benchmark Index_GI is 4209969419, 0% below its average volume of 4209969920.

Oslo Børs Benchmark Index_GI Range

Regarding Oslo Børs Benchmark Index_GI's daily highs and lows, it's 1.9% down from its trailing 24 hours low of kr1,440.55 and 2.98% down from its trailing 24 hours high of kr1,456.63.

About Oslo Børs Benchmark Index_GI's yearly highs and lows, it's 19.75% up from its 52-week low and 2.98% down from its 52-week high.

Volatility

Oslo Børs Benchmark Index_GI's last week, last month's, and last quarter's current intraday variation average was 0.15%, 0.28%, and 0.47%, respectively.

Oslo Børs Benchmark Index_GI's highest amplitude of average volatility was 0.51% (last week), 0.51% (last month), and 0.47% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Oslo Børs Benchmark Index_GI's is considered to be oversold (<=20).

More news about Oslo Børs Benchmark Index_GI (OSEBX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com